Implied BBMC Analyst Target Price: $111
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 23 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Price: The JPMorgan BetaBuilders US Mid Cap Equity ETF (BBMC) has an implied analyst target price of $111.14, indicating a potential upside of 10.85% from its current trading price of $100.26.
Notable Holdings Upside: Key underlying holdings such as Tenet Healthcare Corp., Badger Meter Inc., and Pinnacle Financial Partners Inc. show significant upside potential based on analyst target prices, raising questions about the validity of these targets amidst market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy THC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on THC
Wall Street analysts forecast THC stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 164.770
Low
229.00
Averages
242.89
High
260.00
Current: 164.770
Low
229.00
Averages
242.89
High
260.00
About THC
Tenet Healthcare Corporation is a diversified healthcare services company. The Company's segments include Hospital Operations and Services (Hospital Operations) and Ambulatory Care. The Hospital Operations segment consists of its acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. The Company's subsidiaries operate approximately 50 hospitals serving primarily urban and suburban communities in eight states. The Hospital Operations segment also includes around 132 outpatient facilities, including urgent care centers, imaging centers, off-campus hospital emergency department and micro hospitals. It also provides revenue cycle management and value based care services. Ambulatory Care segment, through its USPI Holding Company, Inc. subsidiary, holds ownership interests in approximately 533 ambulatory surgery centers, and 26 surgical hospitals in 37 states. It also operates a Global Business Center in the Philippines.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenet Fintech Closes Non-Brokered Private Placement
- Financing Size: Tenet Fintech has completed a non-brokered private placement issuing 55.2 million common shares at $0.05 each, raising a total of $2.76 million, which will be used to cover urgent short-term financial obligations such as rent and legal expenses.
- Trading Restrictions: Due to the failure-to-file cease trade order imposed on May 7, 2025, all newly issued securities will remain subject to trading restrictions until the order is fully lifted, impacting the company's liquidity and ability to raise further capital.
- Regulatory Dynamics: This financing follows the partial revocation order issued by the Ontario Securities Commission on May 25, 2026; while the partial revocation is a positive step, it does not guarantee a full revocation in the future, adding uncertainty for investors.
- Strategic Goals: Tenet is actively working to remedy the default that led to the cease trade order, and successfully lifting the order will enable the company to raise additional operational capital, thereby supporting its business development and market expansion plans.
See More
Profitable Companies May Not Last
- Warner Music Group Struggles: Warner Music Group (WMG) has seen only 8.7% annual revenue growth over the past five years, lagging behind its consumer discretionary peers, indicating a lack of competitive strength, and is expected to face deteriorating cash conversion capabilities, leading to declining investment value.
- Itron's Weak Growth: Itron (ITRI) reported a mere 1.4% annual revenue growth over the last two years, falling short of industrial sector standards, with projected sales growth of only 2.4% over the next 12 months reflecting weak demand, while a 6.5% return on capital indicates management's struggles in identifying profitable growth opportunities.
- Tenet Healthcare's Strong Performance: Tenet Healthcare (THC) has achieved a 16.8% annual earnings per share growth through share buybacks, outpacing revenue growth, and has increased its free cash flow margin by 12.7 percentage points over the past five years, enhancing its capacity for growth initiatives and share repurchases.
- Industry-Leading Capital Returns: Tenet Healthcare boasts a 22.5% return on capital, showcasing management's skill in identifying high-return investments, with returns continuing to grow as the company capitalizes on improving market opportunities.
See More
Tenet Healthcare Reports Strong Q1 2026 Earnings Amid Challenges
- Strong Financial Performance: Tenet Healthcare reported net operating revenues of $5.4 billion and adjusted EBITDA of $1.16 billion in Q1 2026, achieving an adjusted EBITDA margin of 21.6%, demonstrating resilience and profitability amid challenging market conditions.
- Robust Cash Flow Generation: The company generated $978 million in adjusted free cash flow during the first quarter, indicating strong operational efficiency and capital management capabilities, which are expected to support future investments and shareholder returns.
- Accelerated Acquisition Activity: Tenet invested $125 million to acquire 7 ambulatory surgical centers in Q1, reflecting its proactive strategy to expand business and market share, aimed at enhancing overall service capacity and competitive advantage.
- Stable Outlook: Management reaffirmed the full-year 2026 guidance, expecting consolidated adjusted EBITDA for Q2 to be 24% to 25% of the full-year target, indicating confidence in future performance despite challenges related to Medicaid and payer disputes.
See More
Tenet (THC) Q1 2026 Earnings Call Transcript
See More
Tenet Healthcare Q1 2026 Earnings Highlights
- Earnings Beat: Tenet Healthcare reported a Q1 non-GAAP EPS of $4.82, exceeding expectations by $0.65, which reflects strong profitability and boosts investor confidence in the company's financial health.
- Revenue Miss: The Q1 revenue of $5.37 billion, representing a year-over-year growth of only 2.9%, fell short of market expectations by $30 million, indicating challenges in revenue growth amid a competitive healthcare landscape.
- EBITDA Growth: The adjusted EBITDA for Q1 2026 reached $484 million, marking a 6.1% increase from the previous year, demonstrating the company's effective cost management and operational efficiency improvements.
- Stable Outlook: Tenet maintains its adjusted EBITDA outlook for FY 2026 in the range of $4.485 billion to $4.785 billion, reflecting confidence in future performance despite market fluctuations.
See More
Tenet Healthcare to Announce Q1 Earnings on April 30
- Earnings Announcement: Tenet Healthcare (THC) is set to release its Q1 2023 earnings on April 30 before market open, with consensus EPS estimated at $4.17, reflecting a 4.4% year-over-year decline, while revenue is projected at $5.4 billion, indicating a 3.4% year-over-year increase.
- Historical Performance: Over the past two years, THC has exceeded EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's strong stability and reliability in financial performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen five upward revisions and nine downward revisions, while revenue estimates experienced one upward revision and eleven downward revisions, indicating market uncertainty and divergence regarding the company's future performance.
- Market Attention: Tenet Healthcare presented at the Barclays 28th Annual Global Healthcare Conference, and despite a 17.3% surge in stock price post-earnings, the market remains focused on its future performance, reflecting ongoing investor interest in the healthcare sector.
See More
Tenet Fintech Closes Non-Brokered Private Placement
- Financing Size: Tenet Fintech has completed a non-brokered private placement issuing 55.2 million common shares at $0.05 each, raising a total of $2.76 million, which will be used to cover urgent short-term financial obligations such as rent and legal expenses.
- Trading Restrictions: Due to the failure-to-file cease trade order imposed on May 7, 2025, all newly issued securities will remain subject to trading restrictions until the order is fully lifted, impacting the company's liquidity and ability to raise further capital.
- Regulatory Dynamics: This financing follows the partial revocation order issued by the Ontario Securities Commission on May 25, 2026; while the partial revocation is a positive step, it does not guarantee a full revocation in the future, adding uncertainty for investors.
- Strategic Goals: Tenet is actively working to remedy the default that led to the cease trade order, and successfully lifting the order will enable the company to raise additional operational capital, thereby supporting its business development and market expansion plans.
See More
Profitable Companies May Not Last
- Warner Music Group Struggles: Warner Music Group (WMG) has seen only 8.7% annual revenue growth over the past five years, lagging behind its consumer discretionary peers, indicating a lack of competitive strength, and is expected to face deteriorating cash conversion capabilities, leading to declining investment value.
- Itron's Weak Growth: Itron (ITRI) reported a mere 1.4% annual revenue growth over the last two years, falling short of industrial sector standards, with projected sales growth of only 2.4% over the next 12 months reflecting weak demand, while a 6.5% return on capital indicates management's struggles in identifying profitable growth opportunities.
- Tenet Healthcare's Strong Performance: Tenet Healthcare (THC) has achieved a 16.8% annual earnings per share growth through share buybacks, outpacing revenue growth, and has increased its free cash flow margin by 12.7 percentage points over the past five years, enhancing its capacity for growth initiatives and share repurchases.
- Industry-Leading Capital Returns: Tenet Healthcare boasts a 22.5% return on capital, showcasing management's skill in identifying high-return investments, with returns continuing to grow as the company capitalizes on improving market opportunities.
See More
Tenet Healthcare Reports Strong Q1 2026 Earnings Amid Challenges
- Strong Financial Performance: Tenet Healthcare reported net operating revenues of $5.4 billion and adjusted EBITDA of $1.16 billion in Q1 2026, achieving an adjusted EBITDA margin of 21.6%, demonstrating resilience and profitability amid challenging market conditions.
- Robust Cash Flow Generation: The company generated $978 million in adjusted free cash flow during the first quarter, indicating strong operational efficiency and capital management capabilities, which are expected to support future investments and shareholder returns.
- Accelerated Acquisition Activity: Tenet invested $125 million to acquire 7 ambulatory surgical centers in Q1, reflecting its proactive strategy to expand business and market share, aimed at enhancing overall service capacity and competitive advantage.
- Stable Outlook: Management reaffirmed the full-year 2026 guidance, expecting consolidated adjusted EBITDA for Q2 to be 24% to 25% of the full-year target, indicating confidence in future performance despite challenges related to Medicaid and payer disputes.
See More
Tenet (THC) Q1 2026 Earnings Call Transcript
See More
Tenet Healthcare Q1 2026 Earnings Highlights
- Earnings Beat: Tenet Healthcare reported a Q1 non-GAAP EPS of $4.82, exceeding expectations by $0.65, which reflects strong profitability and boosts investor confidence in the company's financial health.
- Revenue Miss: The Q1 revenue of $5.37 billion, representing a year-over-year growth of only 2.9%, fell short of market expectations by $30 million, indicating challenges in revenue growth amid a competitive healthcare landscape.
- EBITDA Growth: The adjusted EBITDA for Q1 2026 reached $484 million, marking a 6.1% increase from the previous year, demonstrating the company's effective cost management and operational efficiency improvements.
- Stable Outlook: Tenet maintains its adjusted EBITDA outlook for FY 2026 in the range of $4.485 billion to $4.785 billion, reflecting confidence in future performance despite market fluctuations.
See More
Tenet Healthcare to Announce Q1 Earnings on April 30
- Earnings Announcement: Tenet Healthcare (THC) is set to release its Q1 2023 earnings on April 30 before market open, with consensus EPS estimated at $4.17, reflecting a 4.4% year-over-year decline, while revenue is projected at $5.4 billion, indicating a 3.4% year-over-year increase.
- Historical Performance: Over the past two years, THC has exceeded EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's strong stability and reliability in financial performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen five upward revisions and nine downward revisions, while revenue estimates experienced one upward revision and eleven downward revisions, indicating market uncertainty and divergence regarding the company's future performance.
- Market Attention: Tenet Healthcare presented at the Barclays 28th Annual Global Healthcare Conference, and despite a 17.3% surge in stock price post-earnings, the market remains focused on its future performance, reflecting ongoing investor interest in the healthcare sector.
See More
